+1-610-668-CORE (2673) info@corehf.com

We partnered with kaleo, Inc. in the conduct of a simulated-use human factors validation study of a 0.1-mg epinephrine auto-injector that was developed to potentially help minimize the risk of striking bone during epinephrine injection in patients who weigh 7.5–15 kg (e.g., infants and young children). The findings of the study were presented as a poster at the 2018 American Academy of Allergy Asthma & Immunology Annual Meeting in Orlando Florida. The full text of the article is now available online in the Allergy and Asthma Proceedings.